At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
AGN-214868 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating AGN-214868 and AGN-214868 placebo for Urinary Bladder, Overactive. Completed, enrolled 160 participants across 3 sites in 3 countries.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesFrance, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartOct 2010
Primary CompletionFeb 2013
Study CompletionMay 2013
TodayJul 2026
First PostedJul 7, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.0 years ago
Interventions
AGN-214868drug
AGN-214868 injected into the bladder.
AGN-214868 placebodrug
AGN-214868 placebo injected into the bladder.